Cargando…
Clinical Features of Patients With COVID‐19 With Nonalcoholic Fatty Liver Disease
Previous studies reported that coronavirus disease 2019 (COVID‐19) was likely to result in liver injury. However, few studies investigated liver injury in patients with COVID‐19 with chronic liver diseases. We described the clinical features in patients with COVID‐19 with nonalcoholic fatty liver di...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7436597/ https://www.ncbi.nlm.nih.gov/pubmed/32838108 http://dx.doi.org/10.1002/hep4.1592 |
_version_ | 1783572534809067520 |
---|---|
author | Huang, Rui Zhu, Li Wang, Jian Xue, Leyang Liu, Longgen Yan, Xuebing Huang, Songping Li, Yang Yan, Xiaomin Zhang, Biao Xu, Tianmin Li, Chunyang Ji, Fang Ming, Fang Zhao, Yun Cheng, Juan Wang, Yinling Zhao, Haiyan Hong, Shuqin Chen, Kang Zhao, Xiang‐an Zou, Lei Sang, Dawen Shao, Huaping Guan, Xinying Chen, Xiaobing Chen, Yuxin Wei, Jie Zhu, Chuanwu Wu, Chao |
author_facet | Huang, Rui Zhu, Li Wang, Jian Xue, Leyang Liu, Longgen Yan, Xuebing Huang, Songping Li, Yang Yan, Xiaomin Zhang, Biao Xu, Tianmin Li, Chunyang Ji, Fang Ming, Fang Zhao, Yun Cheng, Juan Wang, Yinling Zhao, Haiyan Hong, Shuqin Chen, Kang Zhao, Xiang‐an Zou, Lei Sang, Dawen Shao, Huaping Guan, Xinying Chen, Xiaobing Chen, Yuxin Wei, Jie Zhu, Chuanwu Wu, Chao |
author_sort | Huang, Rui |
collection | PubMed |
description | Previous studies reported that coronavirus disease 2019 (COVID‐19) was likely to result in liver injury. However, few studies investigated liver injury in patients with COVID‐19 with chronic liver diseases. We described the clinical features in patients with COVID‐19 with nonalcoholic fatty liver disease (NAFLD). Confirmed patients with COVID‐19 from hospitals in 10 cities of Jiangsu Province, China, were retrospectively included between January 18, 2020, and February 26, 2020. The hepatic steatosis index (HSI) was used to defined NAFLD. A total of 280 patients with COVID‐19 were enrolled. Eighty‐six (30.7%) of 280 patients with COVID‐19 were diagnosed as NAFLD by HSI. One hundred (35.7%) patients presented abnormal liver function on admission. The median alanine aminotransferase (ALT) levels (34.5 U/L vs. 23.0 U/L; P < 0.001) and the proportion of elevated ALT (>40 U/L) (40.7% vs. 10.8%; P < 0.001) were significantly higher in patients with NAFLD than in patients without NAFLD on admission. The proportion of elevated ALT in patients with NAFLD was also significantly higher than patients without NAFLD (65.1% vs. 38.7%; P < 0.001) during hospitalization. Multivariate analysis showed that age over 50 years (odds ratio [OR], 2.077; 95% confidence interval [CI], 1.183, 3.648; P = 0.011) and concurrent NAFLD (OR, 2.956; 95% CI, 1.526, 5.726; P = 0.001) were independent risk factors of ALT elevation in patients with COVID‐19, while the atomized inhalation of interferon α‐2b (OR, 0.402; 95% CI, 0.236, 0.683; P = 0.001) was associated with a reduced risk of ALT elevation during hospitalization. No patient developed liver failure or death during hospitalization. The complications and clinical outcomes were comparable between patients with COVID‐19 with and without NAFLD. Conclusion: Patients with NAFLD are more likely to develop liver injury when infected by COVID‐19. However, no patient developed severe liver‐related complications during hospitalization. |
format | Online Article Text |
id | pubmed-7436597 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-74365972020-08-19 Clinical Features of Patients With COVID‐19 With Nonalcoholic Fatty Liver Disease Huang, Rui Zhu, Li Wang, Jian Xue, Leyang Liu, Longgen Yan, Xuebing Huang, Songping Li, Yang Yan, Xiaomin Zhang, Biao Xu, Tianmin Li, Chunyang Ji, Fang Ming, Fang Zhao, Yun Cheng, Juan Wang, Yinling Zhao, Haiyan Hong, Shuqin Chen, Kang Zhao, Xiang‐an Zou, Lei Sang, Dawen Shao, Huaping Guan, Xinying Chen, Xiaobing Chen, Yuxin Wei, Jie Zhu, Chuanwu Wu, Chao Hepatol Commun Original Articles Previous studies reported that coronavirus disease 2019 (COVID‐19) was likely to result in liver injury. However, few studies investigated liver injury in patients with COVID‐19 with chronic liver diseases. We described the clinical features in patients with COVID‐19 with nonalcoholic fatty liver disease (NAFLD). Confirmed patients with COVID‐19 from hospitals in 10 cities of Jiangsu Province, China, were retrospectively included between January 18, 2020, and February 26, 2020. The hepatic steatosis index (HSI) was used to defined NAFLD. A total of 280 patients with COVID‐19 were enrolled. Eighty‐six (30.7%) of 280 patients with COVID‐19 were diagnosed as NAFLD by HSI. One hundred (35.7%) patients presented abnormal liver function on admission. The median alanine aminotransferase (ALT) levels (34.5 U/L vs. 23.0 U/L; P < 0.001) and the proportion of elevated ALT (>40 U/L) (40.7% vs. 10.8%; P < 0.001) were significantly higher in patients with NAFLD than in patients without NAFLD on admission. The proportion of elevated ALT in patients with NAFLD was also significantly higher than patients without NAFLD (65.1% vs. 38.7%; P < 0.001) during hospitalization. Multivariate analysis showed that age over 50 years (odds ratio [OR], 2.077; 95% confidence interval [CI], 1.183, 3.648; P = 0.011) and concurrent NAFLD (OR, 2.956; 95% CI, 1.526, 5.726; P = 0.001) were independent risk factors of ALT elevation in patients with COVID‐19, while the atomized inhalation of interferon α‐2b (OR, 0.402; 95% CI, 0.236, 0.683; P = 0.001) was associated with a reduced risk of ALT elevation during hospitalization. No patient developed liver failure or death during hospitalization. The complications and clinical outcomes were comparable between patients with COVID‐19 with and without NAFLD. Conclusion: Patients with NAFLD are more likely to develop liver injury when infected by COVID‐19. However, no patient developed severe liver‐related complications during hospitalization. John Wiley and Sons Inc. 2020-09-02 /pmc/articles/PMC7436597/ /pubmed/32838108 http://dx.doi.org/10.1002/hep4.1592 Text en © 2020 The Authors. Hepatology Communications published by Wiley Periodicals LLC on behalf of American Association for the Study of Liver Diseases. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Articles Huang, Rui Zhu, Li Wang, Jian Xue, Leyang Liu, Longgen Yan, Xuebing Huang, Songping Li, Yang Yan, Xiaomin Zhang, Biao Xu, Tianmin Li, Chunyang Ji, Fang Ming, Fang Zhao, Yun Cheng, Juan Wang, Yinling Zhao, Haiyan Hong, Shuqin Chen, Kang Zhao, Xiang‐an Zou, Lei Sang, Dawen Shao, Huaping Guan, Xinying Chen, Xiaobing Chen, Yuxin Wei, Jie Zhu, Chuanwu Wu, Chao Clinical Features of Patients With COVID‐19 With Nonalcoholic Fatty Liver Disease |
title | Clinical Features of Patients With COVID‐19 With Nonalcoholic Fatty Liver Disease |
title_full | Clinical Features of Patients With COVID‐19 With Nonalcoholic Fatty Liver Disease |
title_fullStr | Clinical Features of Patients With COVID‐19 With Nonalcoholic Fatty Liver Disease |
title_full_unstemmed | Clinical Features of Patients With COVID‐19 With Nonalcoholic Fatty Liver Disease |
title_short | Clinical Features of Patients With COVID‐19 With Nonalcoholic Fatty Liver Disease |
title_sort | clinical features of patients with covid‐19 with nonalcoholic fatty liver disease |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7436597/ https://www.ncbi.nlm.nih.gov/pubmed/32838108 http://dx.doi.org/10.1002/hep4.1592 |
work_keys_str_mv | AT huangrui clinicalfeaturesofpatientswithcovid19withnonalcoholicfattyliverdisease AT zhuli clinicalfeaturesofpatientswithcovid19withnonalcoholicfattyliverdisease AT wangjian clinicalfeaturesofpatientswithcovid19withnonalcoholicfattyliverdisease AT xueleyang clinicalfeaturesofpatientswithcovid19withnonalcoholicfattyliverdisease AT liulonggen clinicalfeaturesofpatientswithcovid19withnonalcoholicfattyliverdisease AT yanxuebing clinicalfeaturesofpatientswithcovid19withnonalcoholicfattyliverdisease AT huangsongping clinicalfeaturesofpatientswithcovid19withnonalcoholicfattyliverdisease AT liyang clinicalfeaturesofpatientswithcovid19withnonalcoholicfattyliverdisease AT yanxiaomin clinicalfeaturesofpatientswithcovid19withnonalcoholicfattyliverdisease AT zhangbiao clinicalfeaturesofpatientswithcovid19withnonalcoholicfattyliverdisease AT xutianmin clinicalfeaturesofpatientswithcovid19withnonalcoholicfattyliverdisease AT lichunyang clinicalfeaturesofpatientswithcovid19withnonalcoholicfattyliverdisease AT jifang clinicalfeaturesofpatientswithcovid19withnonalcoholicfattyliverdisease AT mingfang clinicalfeaturesofpatientswithcovid19withnonalcoholicfattyliverdisease AT zhaoyun clinicalfeaturesofpatientswithcovid19withnonalcoholicfattyliverdisease AT chengjuan clinicalfeaturesofpatientswithcovid19withnonalcoholicfattyliverdisease AT wangyinling clinicalfeaturesofpatientswithcovid19withnonalcoholicfattyliverdisease AT zhaohaiyan clinicalfeaturesofpatientswithcovid19withnonalcoholicfattyliverdisease AT hongshuqin clinicalfeaturesofpatientswithcovid19withnonalcoholicfattyliverdisease AT chenkang clinicalfeaturesofpatientswithcovid19withnonalcoholicfattyliverdisease AT zhaoxiangan clinicalfeaturesofpatientswithcovid19withnonalcoholicfattyliverdisease AT zoulei clinicalfeaturesofpatientswithcovid19withnonalcoholicfattyliverdisease AT sangdawen clinicalfeaturesofpatientswithcovid19withnonalcoholicfattyliverdisease AT shaohuaping clinicalfeaturesofpatientswithcovid19withnonalcoholicfattyliverdisease AT guanxinying clinicalfeaturesofpatientswithcovid19withnonalcoholicfattyliverdisease AT chenxiaobing clinicalfeaturesofpatientswithcovid19withnonalcoholicfattyliverdisease AT chenyuxin clinicalfeaturesofpatientswithcovid19withnonalcoholicfattyliverdisease AT weijie clinicalfeaturesofpatientswithcovid19withnonalcoholicfattyliverdisease AT zhuchuanwu clinicalfeaturesofpatientswithcovid19withnonalcoholicfattyliverdisease AT wuchao clinicalfeaturesofpatientswithcovid19withnonalcoholicfattyliverdisease |